Nurix TherapeuticsNRIX
About: Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Employees: 284
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 18
79% more capital invested
Capital invested by funds: $756M [Q1] → $1.36B (+$601M) [Q2]
33% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 45
26% more funds holding
Funds holding: 137 [Q1] → 173 (+36) [Q2]
4.38% more ownership
Funds ownership: 105.2% [Q1] → 109.58% (+4.38%) [Q2]
54% less call options, than puts
Call options by funds: $1.05M | Put options by funds: $2.28M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Oppenheimer Mark Breidenbach 25% 1-year accuracy 1 / 4 met price target | 36%upside $30 | Outperform Maintained | 4 Sept 2024 |
Oppenheimer Mark Breidenbach 25% 1-year accuracy 1 / 4 met price target | 23%upside $27 | Outperform Maintained | 14 Aug 2024 |
Truist Securities Srikripa Devarakonda 53% 1-year accuracy 10 / 19 met price target | 64%upside $36 | Buy Initiated | 31 Jul 2024 |
JP Morgan Eric Joseph 44% 1-year accuracy 4 / 9 met price target | 55%upside $34 | Overweight Maintained | 15 Jul 2024 |
Barclays Peter Lawson 31% 1-year accuracy 8 / 26 met price target | 41%upside $31 | Overweight Maintained | 15 Jul 2024 |
Financial journalist opinion
Based on 3 articles about NRIX published over the past 30 days